Supplementary Tables

Supplementary Table S1. The assortment of drug classification.

Item	Classification											
Interventions	Anthracycline				Raltitrexed	Pyrimidine		Mitomycin	Platinum			Ethanol
Specific Agents	Doxorubicin	Epirubicin	Adriamycin	Pirarubicin	Raltitrexed	Fluorouracil	Gemcitabine	Mitomycin	Cisplatin	Miriplatin	Lobaplatin	Ethanol

Supplementary Table S2. Pooled comparisons of hazard ratios regarding response rate.

Items	Comparisons [OR (95%CI)]

Response rate regarding different interventions

1	2	3	4	5	6	7	8	9	10
Anthracycline	2.48 (1.01, 6.32)	4.51 (2.04, 12.39)	2.83 (0.16, 75.11)	0.89 (0.70, 1.12)	1.68 (1.12, 2.50)	3.69 (1.97, 7.39)	1.11 (0.50, 2.55)	0.88 (0.52, 1.51)	2.00 (1.18, 3.32)
0.40 (0.16, 0.99)	Anthracycline + Mitomycin	1.84 (0.84, 4.10)	1.15 (0.05, 30.93)	0.36 (0.14, 0.90)	0.68 (0.24, 1.86)	1.47 (0.49, 5.15)	0.46 (0.13, 1.55)	0.35 (0.13, 0.98)	0.81 (0.28, 2.25)
0.22 (0.08, 0.49)	0.54 (0.24, 1.19)	Anthracycline + Mitomycin + Pyrimidine	0.65 (0.03, 14.80)	0.20 (0.07, 0.45)	0.37 (0.12, 0.92)	0.81 (0.25, 2.48)	0.24 (0.07, 0.84)	0.20 (0.06, 0.49)	0.44 (0.14, 1.16)
0.35 (0.01, 6.09)	0.87 (0.03, 18.45)	1.53 (0.07, 34.66)	Ethanol	0.31 (0.01, 5.62)	0.58 (0.02, 11.67)	1.29 (0.05, 25.61)	0.38 (0.02, 8.23)	0.31 (0.01, 5.88)	0.73 (0.03, 14.33)
1.12 (0.89, 1.43)	2.79 (1.11, 7.06)	5.03 (2.21, 13.96)	3.22 (0.18, 90.39)	Bland	1.88 (1.25, 2.84)	4.15 (2.13, 8.41)	1.24 (0.56, 3.00)	0.99 (0.56, 1.74)	2.22 (1.29, 3.93)
0.60 (0.40, 0.89)	1.48 (0.54, 4.10)	2.70 (1.09, 8.20)	1.72 (0.09, 48.77)	0.53 (0.35, 0.80)	Platinum	2.20 (1.05, 5.03)	0.66 (0.28, 1.77)	0.53 (0.27, 1.00)	1.21 (0.60, 2.24)
0.27 (0.14, 0.51)	0.68 (0.19, 2.05)	1.23 (0.40, 4.01)	0.78 (0.04, 20.58)	0.24 (0.12, 0.47)	0.46 (0.20, 0.95)	Platinum + Anthracycline + Mitomycin	0.30 (0.10, 0.87)	0.24 (0.10, 0.57)	0.54 (0.23, 1.21)
0.90 (0.39, 2.01)	2.20 (0.64, 7.84)	4.09 (1.19, 14.33)	2.61 (0.12, 57.95)	0.81 (0.33, 1.80)	1.52 (0.57, 3.51)	3.29 (1.15, 9.53)	Platinum + Anthracycline + Mitomycin + Pyrimidine	0.81 (0.30, 2.02)	1.79 (0.66, 4.79)
1.13 (0.66, 1.93)	2.83 (1.02, 7.86)	4.99 (2.02, 16.25)	3.21 (0.17, 81.42)	1.01 (0.58, 1.77)	1.89 (1.00, 3.76)	4.20 (1.77, 10.26)	1.24 (0.49, 3.31)	Pyrimidine	2.28 (1.36, 3.75)
0.50 (0.30, 0.85)	1.24 (0.44, 3.53)	2.25 (0.86, 6.92)	1.38 (0.07, 37.89)	0.45 (0.25, 0.77)	0.83 (0.45, 1.66)	1.86 (0.83, 4.37)	0.56 (0.21, 1.52)	0.44 (0.27, 0.74)	Raltitrexed

Response rate regarding specific agents

1	2	3	4	5	6	7	8	9	10	11	12	13
Adriamycin	1.97 (0.91, 5.03)	1.13 (0.62, 2.32)	2.61 (0.89, 7.84)	5.30 (1.91, 15.61)	1.17 (0.62, 2.79)	1.26 (0.48, 4.35)	4.45 (1.83, 12.82)	1.08 (0.04, 47.67)	1.01 (0.48, 2.33)	1.43 (0.52, 4.27)	0.99 (0.57, 1.91)	2.25 (1.07, 5.23)
0.51 (0.20, 1.10)	Cisplatin	0.53 (0.32, 1.00)	1.29 (0.46, 4.01)	2.56 (0.81, 7.60)	0.58 (0.33, 1.11)	0.62 (0.26, 1.79)	2.27 (0.98, 5.24)	0.52 (0.02, 24.02)	0.50 (0.22, 1.05)	0.70 (0.28, 1.87)	0.50 (0.29, 0.82)	1.13 (0.52, 2.34)
0.89 (0.43, 1.61)	1.87 (1.00, 3.08)	Doxorubicin	2.33 (0.91, 5.43)	4.67 (1.97, 10.78)	1.07 (0.78, 1.51)	1.10 (0.54, 2.68)	4.00 (2.00, 7.60)	1.02 (0.04, 35.93)	0.88 (0.57, 1.41)	1.23 (0.60, 2.77)	0.90 (0.68, 1.11)	2.04 (1.26, 3.07)
0.38 (0.13, 1.13)	0.78 (0.25, 2.19)	0.43 (0.18, 1.10)	Doxorubicin + Mitomycin	2.02 (0.92, 4.35)	0.46 (0.18, 1.22)	0.52 (0.15, 1.60)	1.67 (0.63, 5.20)	0.59 (0.01, 17.32)	0.41 (0.15, 0.94)	0.53 (0.18, 1.75)	0.38 (0.14, 1.06)	0.88 (0.34, 2.37)
0.19 (0.06, 0.52)	0.39 (0.13, 1.24)	0.21 (0.09, 0.51)	0.50 (0.23, 1.08)	Doxorubicin + Mitomycin + Gemcitabine	0.23 (0.10, 0.66)	0.24 (0.08, 0.85)	0.85 (0.32, 2.92)	0.27 (0.01, 8.38)	0.21 (0.08, 0.50)	0.26 (0.09, 0.86)	0.19 (0.08, 0.47)	0.44 (0.17, 1.06)
0.85 (0.36, 1.61)	1.73 (0.90, 3.08)	0.93 (0.66, 1.27)	2.16 (0.82, 5.53)	4.35 (1.51, 10.40)	Epirubicin	1.05 (0.51, 2.25)	3.77 (1.92, 6.78)	0.92 (0.03, 32.62)	0.83 (0.42, 1.49)	1.15 (0.60, 2.38)	0.84 (0.56, 1.21)	1.89 (1.06, 3.17)
0.80 (0.23, 2.07)	1.62 (0.56, 3.92)	0.91 (0.37, 1.84)	1.92 (0.62, 6.69)	4.22 (1.18, 12.37)	0.95 (0.44, 1.97)	Epirubicin + Cisplatin + Mitomycin + Furuorouracil	3.59 (1.21, 8.85)	1.16 (0.03, 32.30)	0.84 (0.30, 1.84)	1.07 (0.37, 3.09)	0.80 (0.32, 1.69)	1.80 (0.68, 4.18)
0.22 (0.08, 0.55)	0.44 (0.19, 1.02)	0.25 (0.13, 0.50)	0.60 (0.19, 1.58)	1.17 (0.34, 3.16)	0.27 (0.15, 0.52)	0.28 (0.11, 0.82)	Epirubicin + Lobaplatin + Mitomycin	0.23 (0.01, 9.69)	0.23 (0.09, 0.54)	0.31 (0.13, 0.78)	0.22 (0.11, 0.47)	0.50 (0.22, 1.15)
0.93 (0.02, 25.69)	1.93 (0.04, 47.52)	0.98 (0.03, 27.76)	1.69 (0.06, 101.84)	3.64 (0.12, 152.08)	1.08 (0.03, 32.69)	0.86 (0.03, 31.43)	4.27 (0.10, 140.38)	Ethanol	0.76 (0.02, 27.89)	1.19 (0.04, 41.67)	0.90 (0.02, 22.57)	1.96 (0.05, 60.36)
0.99 (0.43, 2.09)	2.01 (0.95, 4.56)	1.13 (0.71, 1.75)	2.41 (1.07, 6.88)	4.83 (2.02, 13.23)	1.20 (0.67, 2.35)	1.19 (0.54, 3.37)	4.44 (1.87, 11.06)	1.31 (0.04, 45.24)	Fluorouracil	1.40 (0.55, 3.47)	1.00 (0.57, 1.70)	2.28 (1.36, 3.63)
0.70 (0.23, 1.93)	1.43 (0.54, 3.54)	0.81 (0.36, 1.66)	1.90 (0.57, 5.44)	3.90 (1.16, 10.74)	0.87 (0.42, 1.66)	0.93 (0.32, 2.71)	3.18 (1.28, 7.69)	0.84 (0.02, 26.66)	0.72 (0.29, 1.81)	Miriplatin	0.71 (0.31, 1.54)	1.59 (0.66, 3.88)
1.01 (0.52, 1.76)	2.01 (1.22, 3.41)	1.11 (0.90, 1.46)	2.61 (0.94, 6.94)	5.24 (2.13, 13.20)	1.19 (0.83, 1.79)	1.25 (0.59, 3.14)	4.55 (2.13, 8.84)	1.12 (0.04, 43.03)	1.00 (0.59, 1.76)	1.40 (0.65, 3.20)	Bland	2.25 (1.33, 3.86)
0.44 (0.19, 0.94)	0.88 (0.43, 1.93)	0.49 (0.33, 0.79)	1.13 (0.42, 2.96)	2.28 (0.95, 5.79)	0.53 (0.32, 0.95)	0.56 (0.24, 1.46)	2.00 (0.87, 4.46)	0.51 (0.02, 20.08)	0.44 (0.28, 0.73)	0.63 (0.26, 1.50)	0.45 (0.26, 0.75)	Raltitrexed

Supplementary Table S3. Pooled comparisons of adverse events.

Items	Comparisons [OR (95%CI)]

Adverse events regarding different interventions

C1	C2	C3	C4	C5	C6	C7	C8	C9	C10
Anthracycline	1.16 (0.33, 4.34)	0.51 (0.16, 1.50)	0.58 (0.27, 1.23)	0.87 (0.59, 1.25)	1.01 (0.81, 1.27)	0.87 (0.56, 1.36)	1.01 (0.50, 2.00)	1.02 (0.03, 29.80)	1.01 (0.03, 42.71)
0.86 (0.23, 2.99)	Anthracycline + Mitomycin	0.44 (0.14, 1.30)	0.49 (0.11, 2.14)	0.75 (0.19, 2.68)	0.87 (0.23, 3.08)	0.75 (0.19, 2.77)	0.86 (0.20, 3.47)	0.89 (0.02, 32.65)	0.88 (0.02, 41.91)
1.95 (0.67, 6.39)	2.27 (0.77, 7.38)	Anthracycline + Mitomycin + Pyrimidine	1.13 (0.29, 4.69)	1.71 (0.53, 5.77)	1.99 (0.66, 6.43)	1.71 (0.54, 5.90)	1.98 (0.55, 7.53)	2.05 (0.05, 73.88)	2.04 (0.04, 97.62)
1.74 (0.81, 3.73)	2.03 (0.47, 9.27)	0.89 (0.21, 3.39)	Ethanol	1.50 (0.65, 3.52)	1.75 (0.79, 3.90)	1.52 (0.63, 3.73)	1.74 (0.63, 4.91)	1.76 (0.05, 55.52)	1.71 (0.04, 83.23)
1.15 (0.80, 1.69)	1.33 (0.37, 5.39)	0.59 (0.17, 1.89)	0.67 (0.28, 1.55)	Bland	1.17 (0.78, 1.75)	1.01 (0.58, 1.80)	1.16 (0.53, 2.51)	1.20 (0.04, 34.84)	1.16 (0.03, 50.50)
0.99 (0.79, 1.24)	1.15 (0.32, 4.39)	0.50 (0.16, 1.53)	0.57 (0.26, 1.26)	0.86 (0.57, 1.28)	Platinum	0.86 (0.53, 1.41)	1.00 (0.48, 2.05)	1.02 (0.03, 28.81)	1.00 (0.03, 41.97)
1.15 (0.73, 1.78)	1.33 (0.36, 5.32)	0.58 (0.17, 1.84)	0.66 (0.27, 1.58)	0.99 (0.55, 1.73)	1.16 (0.71, 1.90)	Platinum + Anthracycline + Mitomycin	1.15 (0.51, 2.60)	1.17 (0.04, 34.75)	1.16 (0.03, 50.35)
0.99 (0.50, 1.99)	1.16 (0.29, 5.09)	0.51 (0.13, 1.82)	0.57 (0.20, 1.59)	0.86 (0.40, 1.90)	1.00 (0.49, 2.08)	0.87 (0.38, 1.98)	Platinum + Anthracycline + Mitomycin + Pyrimidine	1.01 (0.03, 33.89)	0.99 (0.03, 45.20)
0.98 (0.03, 29.90)	1.13 (0.03, 47.17)	0.49 (0.01, 18.56)	0.57 (0.02, 18.59)	0.84 (0.03, 26.81)	0.98 (0.03, 30.13)	0.85 (0.03, 28.31)	0.99 (0.03, 33.99)	Pyrimidine	0.99 (0.03, 39.12)
0.99 (0.02, 34.27)	1.14 (0.02, 54.09)	0.49 (0.01, 22.33)	0.59 (0.01, 22.43)	0.86 (0.02, 30.01)	1.00 (0.02, 34.91)	0.86 (0.02, 30.61)	1.01 (0.02, 36.26)	1.01 (0.03, 36.22)	Raltitrexed

Adverse events regarding specific agents

C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12	C13
Adriamycin	3.92 (1.70, 9.03)	1.30 (0.60, 2.83)	1.55 (0.35, 6.43)	0.65 (0.16, 2.40)	2.60 (1.09, 6.02)	2.53 (0.83, 7.67)	2.27 (0.85, 5.88)	1.48 (0.47, 4.59)	1.24 (0.04, 45.47)	2.37 (0.98, 5.59)	1.26 (0.74, 2.13)	1.23 (0.03, 59.84)
0.25 (0.11, 0.59)	Cisplatin	0.33 (0.17, 0.68)	0.39 (0.09, 1.60)	0.16 (0.04, 0.60)	0.66 (0.34, 1.28)	0.65 (0.25, 1.66)	0.57 (0.26, 1.27)	0.38 (0.14, 1.00)	0.31 (0.01, 11.66)	0.60 (0.30, 1.20)	0.32 (0.17, 0.61)	0.31 (0.01, 14.17)
0.77 (0.35, 1.66)	3.01 (1.48, 6.06)	Doxorubicin	1.19 (0.32, 4.04)	0.51 (0.16, 1.47)	1.99 (1.15, 3.40)	1.96 (0.81, 4.65)	1.74 (0.87, 3.40)	1.14 (0.44, 2.81)	0.96 (0.03, 32.19)	1.81 (1.00, 3.20)	0.97 (0.55, 1.70)	0.94 (0.03, 41.93)
0.64 (0.16, 2.89)	2.53 (0.62, 10.65)	0.84 (0.25, 3.08)	Doxorubicin + Mitomycin	0.42 (0.14, 1.27)	1.68 (0.43, 6.73)	1.66 (0.36, 7.80)	1.45 (0.35, 6.14)	0.96 (0.21, 4.41)	0.81 (0.02, 34.54)	1.53 (0.38, 6.32)	0.81 (0.22, 3.32)	0.80 (0.02, 45.44)
1.53 (0.42, 6.19)	6.07 (1.67, 22.78)	1.97 (0.68, 6.41)	2.37 (0.79, 7.38)	Doxorubicin + Mitomycin + Gemcitabine	3.95 (1.19, 13.87)	3.93 (0.98, 16.52)	3.46 (0.97, 12.93)	2.27 (0.55, 9.76)	1.91 (0.05, 77.21)	3.61 (1.06, 12.97)	1.91 (0.58, 7.04)	1.86 (0.04, 101.15)
0.38 (0.17, 0.92)	1.52 (0.78, 2.96)	0.50 (0.29, 0.87)	0.60 (0.15, 2.32)	0.25 (0.07, 0.84)	Epirubicin	0.98 (0.51, 1.92)	0.87 (0.58, 1.34)	0.57 (0.27, 1.20)	0.48 (0.02, 16.51)	0.91 (0.72, 1.14)	0.48 (0.25, 0.96)	0.48 (0.01, 22.65)
0.40 (0.13, 1.20)	1.53 (0.60, 4.06)	0.51 (0.22, 1.23)	0.60 (0.13, 2.78)	0.25 (0.06, 1.02)	1.02 (0.52, 1.97)	Epirubicin + Cisplatin + Mitomycin + Furuorouracil	0.88 (0.40, 1.95)	0.58 (0.21, 1.55)	0.50 (0.02, 17.46)	0.93 (0.46, 1.88)	0.49 (0.19, 1.28)	0.49 (0.01, 25.07)
0.44 (0.17, 1.17)	1.75 (0.79, 3.82)	0.58 (0.29, 1.15)	0.69 (0.16, 2.86)	0.29 (0.08, 1.03)	1.15 (0.74, 1.74)	1.13 (0.51, 2.52)	Epirubicin + Lobaplatin + Mitomycin	0.66 (0.28, 1.52)	0.55 (0.02, 19.43)	1.05 (0.63, 1.68)	0.56 (0.26, 1.24)	0.54 (0.02, 25.67)
0.68 (0.22, 2.14)	2.64 (1.00, 7.40)	0.88 (0.36, 2.25)	1.05 (0.23, 4.84)	0.44 (0.10, 1.82)	1.76 (0.83, 3.76)	1.72 (0.65, 4.76)	1.52 (0.66, 3.62)	Ethanol	0.85 (0.03, 31.43)	1.59 (0.74, 3.52)	0.85 (0.32, 2.35)	0.84 (0.02, 41.29)
0.81 (0.02, 25.95)	3.19 (0.09, 103.13)	1.04 (0.03, 31.43)	1.24 (0.03, 49.32)	0.52 (0.01, 18.23)	2.09 (0.06, 64.43)	2.02 (0.06, 66.12)	1.82 (0.05, 55.79)	1.18 (0.03, 38.13)	Fluorouracil	1.90 (0.06, 60.34)	1.00 (0.03, 32.46)	0.98 (0.03, 43.77)
0.42 (0.18, 1.02)	1.67 (0.84, 3.29)	0.55 (0.31, 1.00)	0.65 (0.16, 2.60)	0.28 (0.08, 0.94)	1.10 (0.88, 1.38)	1.08 (0.53, 2.17)	0.95 (0.60, 1.58)	0.63 (0.28, 1.35)	0.53 (0.02, 17.81)	Miriplatin	0.54 (0.27, 1.07)	0.52 (0.01, 25.04)
0.79 (0.47, 1.36)	3.11 (1.65, 5.93)	1.03 (0.59, 1.82)	1.24 (0.30, 4.45)	0.52 (0.14, 1.74)	2.06 (1.05, 4.00)	2.02 (0.78, 5.26)	1.79 (0.80, 3.90)	1.17 (0.43, 3.13)	1.00 (0.03, 34.10)	1.87 (0.93, 3.73)	Bland	0.97 (0.03, 45.01)
0.81 (0.02, 30.96)	3.26 (0.07, 118.09)	1.06 (0.02, 37.95)	1.24 (0.02, 60.84)	0.54 (0.01, 23.66)	2.09 (0.04, 77.89)	2.03 (0.04, 79.47)	1.84 (0.04, 66.36)	1.20 (0.02, 44.90)	1.03 (0.02, 33.63)	1.91 (0.04, 68.76)	1.03 (0.02, 36.91)	Raltitrexed

Supplementary Table S4. Pooled comparisons of overall survival rate.

Items	Comparisons [OR (95%CI)]

Overall survival regarding different interventions

Anthracycline	1.18 (0.71, 2.75)	2.43 (1.24, 4.99)	1.93 (0.78, 3.50)	0.80 (0.59, 1.11)	0.68 (0.43, 0.95)	1.84 (1.12, 3.54)	0.64 (0.28, 2.03)	0.90 (0.34, 1.89)	1.27 (0.48, 2.80)
0.85 (0.36, 1.42)	Anthracycline + Mitomycin	2.12 (0.90, 3.37)	1.70 (0.42, 3.17)	0.66 (0.27, 1.21)	0.60 (0.21, 1.02)	1.50 (0.58, 3.42)	0.52 (0.16, 1.84)	0.68 (0.19, 1.69)	0.93 (0.27, 2.46)
0.41 (0.20, 0.81)	0.47 (0.30, 1.12)	Anthracycline + Mitomycin + Pyrimidine	0.80 (0.24, 1.82)	0.33 (0.15, 0.70)	0.28 (0.11, 0.57)	0.72 (0.32, 1.97)	0.26 (0.09, 1.06)	0.39 (0.11, 0.95)	0.54 (0.15, 1.39)
0.52 (0.29, 1.29)	0.59 (0.32, 2.39)	1.26 (0.55, 4.24)	Ethanol	0.42 (0.22, 1.12)	0.35 (0.17, 0.90)	0.88 (0.48, 3.18)	0.30 (0.14, 1.64)	0.58 (0.16, 1.48)	0.81 (0.23, 2.14)
1.24 (0.90, 1.70)	1.51 (0.83, 3.67)	3.03 (1.44, 6.63)	2.40 (0.89, 4.58)	Bland	0.85 (0.52, 1.22)	2.27 (1.30, 4.73)	0.81 (0.33, 2.63)	1.14 (0.39, 2.44)	1.60 (0.56, 3.52)
1.46 (1.05, 2.35)	1.66 (0.98, 4.85)	3.55 (1.74, 8.90)	2.83 (1.11, 5.86)	1.18 (0.82, 1.91)	Platinum	2.68 (1.54, 6.28)	0.85 (0.41, 3.53)	1.41 (0.49, 3.21)	1.99 (0.69, 4.49)
0.54 (0.28, 0.89)	0.67 (0.29, 1.72)	1.39 (0.51, 3.14)	1.14 (0.31, 2.10)	0.44 (0.21, 0.77)	0.37 (0.16, 0.65)	Platinum + Anthracycline + Mitomycin	0.34 (0.12, 1.25)	0.46 (0.15, 1.13)	0.65 (0.20, 1.67)
1.56 (0.49, 3.58)	1.94 (0.54, 6.11)	3.90 (0.95, 10.95)	3.32 (0.61, 6.95)	1.23 (0.38, 2.99)	1.17 (0.28, 2.47)	2.91 (0.80, 8.42)	Platinum + Anthracycline + Mitomycin + Pyrimidine	1.26 (0.28, 3.75)	1.79 (0.39, 5.33)
1.11 (0.53, 2.98)	1.47 (0.59, 5.33)	2.59 (1.06, 9.45)	1.73 (0.67, 6.32)	0.88 (0.41, 2.55)	0.71 (0.31, 2.04)	2.16 (0.88, 6.86)	0.79 (0.27, 3.60)	Pyrimidine	1.47 (0.61, 3.21)
0.79 (0.36, 2.08)	1.07 (0.41, 3.76)	1.87 (0.72, 6.54)	1.24 (0.47, 4.26)	0.62 (0.28, 1.80)	0.50 (0.22, 1.46)	1.54 (0.60, 4.92)	0.56 (0.19, 2.55)	0.68 (0.31, 1.63)	Raltitrexed

Overall survival regarding specific agents

Adriamycin	0.32 (0.17, 0.64)	0.60 (0.34, 1.03)	0.85 (0.32, 2.07)	1.60 (0.72, 3.85)	0.44 (0.23, 0.93)	0.50 (0.16, 1.76)	0.87 (0.41, 2.26)	0.71 (0.27, 2.01)	0.41 (0.17, 1.11)	0.22 (0.11, 0.50)	0.52 (0.35, 0.83)	0.77 (0.29, 1.98)
3.09 (1.57, 5.90)	Cisplatin	1.89 (1.05, 3.32)	2.51 (1.01, 6.61)	4.64 (2.28, 11.77)	1.35 (0.79, 2.66)	1.50 (0.49, 5.21)	2.66 (1.32, 6.43)	2.15 (0.93, 6.12)	1.23 (0.53, 3.41)	0.69 (0.42, 1.21)	1.60 (1.00, 2.80)	2.32 (0.94, 6.04)
1.67 (0.97, 2.97)	0.53 (0.30, 0.96)	Doxorubicin	1.42 (0.53, 2.79)	2.79 (1.52, 5.02)	0.75 (0.50, 1.28)	0.83 (0.30, 2.62)	1.46 (0.81, 3.23)	1.20 (0.58, 3.07)	0.70 (0.36, 1.52)	0.38 (0.21, 0.75)	0.90 (0.63, 1.33)	1.30 (0.64, 2.71)
1.18 (0.48, 3.12)	0.40 (0.15, 0.99)	0.70 (0.36, 1.90)	Doxorubicin + Mitomycin	1.98 (1.06, 3.33)	0.56 (0.24, 1.20)	0.62 (0.17, 2.08)	1.12 (0.43, 2.78)	0.92 (0.31, 2.44)	0.51 (0.19, 1.25)	0.29 (0.11, 0.67)	0.63 (0.29, 1.57)	1.06 (0.35, 2.18)
0.62 (0.26, 1.39)	0.22 (0.08, 0.44)	0.36 (0.20, 0.66)	0.51 (0.30, 0.94)	Doxorubicin + Mitomycin + Gemcitabine	0.30 (0.13, 0.57)	0.33 (0.09, 1.14)	0.59 (0.23, 1.41)	0.43 (0.16, 1.21)	0.26 (0.11, 0.66)	0.15 (0.06, 0.32)	0.33 (0.16, 0.64)	0.53 (0.19, 1.15)
2.26 (1.07, 4.42)	0.74 (0.38, 1.27)	1.34 (0.78, 2.02)	1.80 (0.83, 4.20)	3.36 (1.74, 7.76)	Epirubicin	1.15 (0.40, 2.98)	2.03 (1.26, 3.27)	1.55 (0.82, 3.28)	0.92 (0.39, 2.20)	0.50 (0.31, 0.80)	1.22 (0.67, 2.01)	1.83 (0.70, 3.91)
2.00 (0.57, 6.42)	0.67 (0.19, 2.02)	1.20 (0.38, 3.37)	1.60 (0.48, 5.79)	3.02 (0.88, 11.21)	0.87 (0.34, 2.49)	Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1.80 (0.60, 6.15)	1.29 (0.43, 5.12)	0.82 (0.20, 3.16)	0.41 (0.15, 1.39)	1.10 (0.33, 3.17)	1.63 (0.38, 5.90)
1.15 (0.44, 2.47)	0.38 (0.16, 0.76)	0.68 (0.31, 1.24)	0.90 (0.36, 2.35)	1.68 (0.71, 4.37)	0.49 (0.31, 0.79)	0.56 (0.16, 1.67)	Epirubicin + Lobaplatin + Mitomycin	0.78 (0.35, 1.86)	0.45 (0.17, 1.24)	0.24 (0.13, 0.51)	0.63 (0.27, 1.19)	0.89 (0.30, 2.28)
1.40 (0.50, 3.68)	0.47 (0.16, 1.07)	0.83 (0.33, 1.74)	1.09 (0.41, 3.27)	2.30 (0.83, 6.09)	0.65 (0.31, 1.21)	0.77 (0.20, 2.30)	1.28 (0.54, 2.85)	Ethanol	0.61 (0.19, 1.73)	0.34 (0.13, 0.71)	0.76 (0.30, 1.74)	1.16 (0.35, 3.16)
2.44 (0.90, 5.92)	0.81 (0.29, 1.89)	1.43 (0.66, 2.77)	1.95 (0.80, 5.35)	3.80 (1.51, 9.38)	1.09 (0.46, 2.57)	1.22 (0.32, 5.01)	2.23 (0.80, 5.97)	1.63 (0.58, 5.39)	Fluorouracil	0.52 (0.21, 1.39)	1.30 (0.54, 2.88)	1.99 (0.91, 3.69)
4.48 (2.00, 8.71)	1.44 (0.82, 2.37)	2.61 (1.33, 4.71)	3.45 (1.50, 9.28)	6.50 (3.10, 16.40)	2.00 (1.25, 3.25)	2.42 (0.72, 6.75)	4.20 (1.98, 7.95)	2.95 (1.41, 7.74)	1.91 (0.72, 4.73)	Miriplatin	2.41 (1.20, 4.06)	3.64 (1.30, 9.01)
1.92 (1.20, 2.83)	0.62 (0.36, 1.00)	1.11 (0.75, 1.60)	1.58 (0.64, 3.40)	3.03 (1.55, 6.17)	0.82 (0.50, 1.50)	0.91 (0.32, 3.01)	1.60 (0.84, 3.71)	1.32 (0.58, 3.30)	0.77 (0.35, 1.84)	0.42 (0.25, 0.83)	Bland	1.43 (0.61, 3.26)
1.29 (0.51, 3.49)	0.43 (0.17, 1.06)	0.77 (0.37, 1.57)	0.95 (0.46, 2.84)	1.88 (0.87, 5.20)	0.55 (0.26, 1.43)	0.61 (0.17, 2.63)	1.12 (0.44, 3.31)	0.86 (0.32, 2.86)	0.50 (0.27, 1.10)	0.27 (0.11, 0.77)	0.70 (0.31, 1.65)	Raltitrexed

Supplementary Table S5. Node-splitting analysis of response rate.

Outcome	Comparison	Direct Effect	Indirect Effect	Overall	*P* value
Response rate regarding different interventions					
	Anthracycline vs. Bland	-0.11 (-0.35, 0.14)	-0.35 (-1.10, 0.42)	-0.13 (-0.35, 0.08)	0.56
	Anthracycline vs. Platinum	0.43 (-0.09, 0.97)	0.70 (-0.01, 1.48)	0.56 (0.16, 0.90)	0.52
	Bland vs. Platinum	0.80 (0.08, 1.34)	0.52 (-0.07, 1.09)	0.69 (0.28, 1.01)	0.63
Response rate regarding specific agents					
	Cisplatin vs.Epirubicin	-0.47 (-1.97, 1.17)	-0.51 (-1.26, 0.16)	-0.52 (-1.34, 0.06)	0.90
	Cisplatin vs.Bland	-0.75 (-1.40, -0.20)	-0.65 (-2.23, 0.85)	-0.71 (-1.48, -0.22)	0.91
	Doxorubicin vs.Epirubicin	0.09 (-0.24, 0.41)	0.27 (-1.49, 1.95)	0.07 (-0.23, 0.40)	0.85
	Doxorubicin vs.Bland	-0.11 (-0.38, 0.14)	-0.12 (-1.84, 1.64)	-0.12 (-0.34, 0.14)	0.98

Supplementary Table S6. Node-splitting analysis of adverse events.

Outcome	Comparison	Direct Effect	Indirect Effect	Overall	*P* value
Adverse events regarding different interventions					
	Anthracycline vs. Bland	-0.22 (-0.57, 0.60)	-0.42 (-1.18, 0.21)	-0.35 (-0.84, 0.39)	0.24
	Anthracycline vs. Platinum	0.10 (-0.31, 0.21)	0.03 (-0.14, 0.37)	0.01 (-0.02, 0.23)	0.33
	Bland vs. Platinum	1.31 (0.62, 2.04)	0.73 (0.29, 1.35)	0.92 (0.42, 1.70)	0.19
Adverse events regarding specific agents					
	Cisplatin vs. Epirubicin	0.42 (-0.84, 1.65)	16.31 (1.82, 60.33)	0.69 (-0.50, 3.02)	0.13
	Cisplatin vs. Miriplatin	-0.49 (-1.60, 0.60)	-0.27 (-0.94, 0.39)	-0.30 (-0.91, 0.30)	0.73
	Cisplatin vs. Bland	-0.45 (-2.57, 1.50)	-0.17 (-0.96, 0.59)	-0.20 (-0.92, 0.54)	0.79
	Doxorubicin vs. Epirubicin	0.67 (-0.71, 2.00)	0.28 (-0.48, 1.05)	0.51 (-0.16, 1.18)	0.62
	Doxorubicin vs. Bland	-2.33 (-4.39, -0.60)	-3.50 (-5.16, -1.92)	-2.97 (-4.30, -1.74)	0.35
	Epirubicin vs. Miriplatin	-1.26 (-3.74, 1.21)	-1.22 (-2.17, -0.29)	-1.18 (-2.04, -0.32)	0.97

Supplementary Table S7. Node-splitting analysis of overall survival rate.

Outcome	Comparison	Direct Effect	Indirect Effect	Overall	*P* value
Overall survival regarding different interventions					
	Anthracycline vs. Bland	-0.30 (-0.71, 0.08)	0.21 (-0.67, 1.12)	-0.23 (-0.55, 0.13)	0.27
	Anthracycline vs. Platinum	-0.23 (-0.84, 0.31)	-0.79 (-1.53, -0.04)	-0.44 (-0.90, -0.01)	0.25
	Bland vs. Platinum	-0.48 (-1.16, 0.18)	0.07 (-0.67, 0.77)	-0.22 (-0.72, 0.23)	0.27
Overall survival regarding specific agents					
	Cisplatin vs. Miriplatin	-0.37 (-1.05, 0.36)	-0.34 (-1.35, 0.86)	-0.31 (-0.94, 0.19)	0.99
	Cisplatin vs. Bland	0.56 (-0.03, 1.05)	0.30 (-0.62, 1.94)	0.53 (-0.04, 0.98)	0.81
	Doxorubicin vs. Epirubicin	-0.23 (-0.81, 0.25)	-0.30 (-1.45, 0.74)	-0.25 (-0.72, 0.23)	0.95
	Doxorubicin vs. Bland	-0.10 (-0.55, 0.28)	0.16 (-1.19, 1.16)	-0.08 (-0.46, 0.29)	0.69
	Epirubicin vs. Miriplatin	-0.68 (-1.24, -0.09)	-0.73 (-1.97, 0.39)	-0.63 (-1.18, -0.15)	0.87

Supplementary Table S8. Summary of findings and evidence qualities for response rate.

Outcomes	Comparison		No. of trails	Hazard ratio (95% CI)	Sample size	Quality of the evidence (GRADE)
Response rate (different interventions)	Anthracycline	Anthracycline + Mitomycin	1	1.85 (1.01, 3.39)	109	⊕ ⊕ ⊕ ⊕
		Ethanol	1	1.03 (0.95, 1.11)	97	⊕ ⊕ ⊕ ⊕
		Bland	4	0.92 (0.82, 1.02)	511	⊕ ⊕ ⊕ ⊕
		Platinum	3	1.25 (0.82, 1.89)	399	⊕ ⊕ ⊕ ⊕
		Platinum + Anthracycline + Mitomycin	1	2.43 (1.61, 3.69)	244	⊕ ⊕ ⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	1.08 (0.71, 1.66)	51	⊕ ⊕ ⊕
		Pyrimidine	1	0.95 (0.75, 1.19)	151	⊕ ⊕ ⊕
		Raltitrexed	1	1.34 (1.10, 1.63)	151	⊕ ⊕ ⊕
		Anthracycline + Mitomycin + Pyrimidine	1	2.57 (1.45, 4.56)	103	⊕ ⊕ ⊕ ⊕
	Anthracycline + Mitomycin	Anthracycline + Mitomycin + Pyrimidine	1	1.39 (0.94, 2.05)	112	⊕ ⊕ ⊕ ⊕
	Bland	Platinum	2	1.27 (1.04, 1.56)	127	⊕ ⊕ ⊕
	Pyrimidine	Raltitrexed	1	1.42 (1.16, 1.73)	152	⊕ ⊕ ⊕
Response rate (specific agents)	Bland	Cisplatin	2	1.27 (1.04, 1.56)	127	⊕ ⊕ ⊕
		Adriamycin	1	1.03 (0.67, 1.56)	249	⊕ ⊕ ⊕
	Epirubicin	Cisplatin	1	1.33 (0.57, 3.12)	28	⊕ ⊕ ⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	1.08 (0.71, 1.66)	51	⊕ ⊕ ⊕
		Epirubicin + Lobaplatin + Mitomycin	1	2.43 (1.61, 3.69)	244	⊕ ⊕ ⊕
		Ethanol	1	1.00 (0.94, 1.07)	97	⊕ ⊕ ⊕ ⊕
		Doxorubicin	1	0.99 (0.92, 1.07)	177	⊕ ⊕ ⊕ ⊕
		Miriplatin	1	1.03 (0.89, 1.19)	198	⊕ ⊕ ⊕ ⊕
	Doxorubicin	Bland	3	0.94 (0.84, 1.05)	262	⊕ ⊕ ⊕ ⊕
		Doxorubicin + Mitomycin	1	1.85 (1.01, 3.39)	109	⊕ ⊕ ⊕ ⊕
		Doxorubicin + Mitomycin + Gemcitabine	1	2.57 (1.45, 4.56)	103	⊕ ⊕ ⊕ ⊕
		Fluorouracil	1	0.95 (0.75, 1.19)	151	⊕ ⊕ ⊕
		Raltitrexed	1	1.34 (1.10, 1.63)	151	⊕ ⊕ ⊕
	Doxorubicin + Mitomycin	Doxorubicin + Mitomycin + Gemcitabine	1	1.39 (0.94, 2.05)	112	⊕ ⊕ ⊕ ⊕
	Raltitrexed	Fluorouracil	1	0.71 (0.58, 0.86)	152	⊕ ⊕ ⊕

GRADE Working Group grades of evidence
High quality (⊕ ⊕ ⊕ ⊕): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (⊕ ⊕ ⊕): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (⊕ ⊕): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (⊕): We are very uncertain about the estimate.
*CI: confidence interval; HR: hazard ratio, MD: mean difference.

Supplementary Table S9. Summary of findings and evidence qualities regarding adverse events.

Outcomes	Comparison		No. of trails	Hazard ratio (95% CI)	Sample size	Quality of the evidence (GRADE)
Adverse event (different interventions)	Anthracycline	Anthracycline + Mitomycin	1	1.00 (0.98, 1.02)	109	⊕⊕⊕⊕
		Anthracycline + Mitomycin + Pyrimidine	1	0.99 (0.97, 1.02)	103	⊕⊕⊕⊕
		Ethanol	1	0.62 (0.36, 1.05)	97	⊕⊕⊕⊕
		Bland	3	1.07 (0.99, 116)	434	⊕⊕⊕⊕
		Platinum	3	0.98 (0.94, 1.03)	473	⊕⊕⊕⊕
		Platinum + Anthracycline + Mitomycin	1	0.92 (0.84, 1.00)	244	⊕⊕⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	1.03 (0.94, 1.13)	51	⊕⊕⊕
		Pyrimidine	1	1.00 (0.96, 1.04)	151	⊕⊕⊕
		Raltitrexed	1	1.00 (0.96, 1.04)	151	⊕⊕⊕
	Anthracycline + Mitomycin	Anthracycline + Mitomycin + Pyrimidine	1	0.99 (0.97, 1.01)	112	⊕⊕⊕⊕
	Bland	Platinum	2	1.43 (1.05, 1.96)	127	⊕⊕⊕
	Pyrimidine	Raltitrexed	1	1.00 (0.96, 1.04)	152	⊕⊕⊕
Adverse event (specific agents)	Bland	Adriamycin	1	0.91 (0.74, 1.12)	249	⊕⊕⊕
		Cisplatin	2	1.45 (1.09, 1.92)	127	⊕⊕⊕
	Epirubicin	Cisplatin	1	0.99 (0.92, 1.07)	28	⊕⊕⊕
		Miriplatin	2	0.98 (0.93, 1.03)	445	⊕⊕⊕⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	1.03 (0.94, 1.12)	51	⊕⊕⊕
		Epirubicin + Lobaplatin + Mitomycin	1	0.92 (0.84, 1.00)	244	⊕⊕⊕
		Ethanol	1	0.76 (0.54, 1.09)	97	⊕⊕⊕⊕
		Doxorubicin	1	0.72 (0.41, 1.26)	177	⊕⊕⊕⊕
	Cisplatin	Epirubicin	1	0.94 (0.70, 1.25)	98	⊕⊕⊕
	Doxorubicin	Bland	2	1.11 (0.99, 1.24)	185	⊕⊕⊕⊕
		Doxorubicin + Mitomycin	1	1.00 (0.98, 1.02)	109	⊕⊕⊕⊕
		Doxorubicin + Mitomycin + Gemcitabine	1	0.99 (0.97, 1.02)	103	⊕⊕⊕⊕
		Fluorouracil	1	1.00 (0.96, 1.04)	151	⊕⊕⊕
		Raltitrexed	1	1.00 (0.96, 1.04)	151	⊕⊕⊕
	Doxorubicin + Mitomycin	Doxorubicin + Mitomycin + Gemcitabine	1	0.99 (0.97, 1.01)	112	⊕⊕⊕⊕
	Raltitrexed	Fluorouracil	1	1.00 (0.96, 1.04)	152	⊕⊕⊕

GRADE Working Group grades of evidence
High quality (⊕⊕⊕⊕): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (⊕⊕⊕): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (⊕⊕): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (⊕): We are very uncertain about the estimate.
*CI: confidence interval; HR: hazard ratio, MD: mean difference.

Supplementary Table S10. Summary of findings and evidence qualities regarding overall survival rate.

| Outcomes	Comparison		No. of trails	Hazard ratio (95% CI)	Sample size	Quality of the evidence (GRADE)
Overall survival (different interventions)	Bland	Platinum	2	0.78 (0.58, 1.05)	127	⊕ ⊕ ⊕
	Anthracycline	Anthracycline + Mitomycin	1	1.40 (0.51, 3.83)	109	⊕ ⊕ ⊕ ⊕
		Anthracycline + Mitomycin + Pyrimidine	1	1.91 (0.52, 7.03)	103	⊕ ⊕ ⊕ ⊕
		Ethanol	1	1.20 (0.96, 1.50)	97	⊕ ⊕ ⊕ ⊕
		Bland	3	0.95 (0.90, 1.01)	434	⊕ ⊕ ⊕ ⊕
		Platinum	2	0.97 (0.84, 1.12)	420	⊕ ⊕ ⊕ ⊕
		Platinum + Anthracycline + Mitomycin	1	1.64 (1.23, 2.20)	244	⊕ ⊕ ⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	0.97 (0.74, 1.28)	51	⊕ ⊕ ⊕
		Pyrimidine	1	0.88 (0.62, 1.25)	151	⊕ ⊕ ⊕
		Raltitrexed	1	1.04 (0.75, 1.44)	151	⊕ ⊕ ⊕
	Anthracycline + Mitomycin	Anthracycline + Mitomycin + Pyrimidine	1	1.25 (0.96, 1.64)	112	⊕ ⊕ ⊕ ⊕
	Pyrimidine	Raltitrexed	1	0.84 (0.60, 1.19)	152	⊕ ⊕ ⊕
Overall survival (specifiv agents)	Cisplatin	Epirubicin	1	0.91 (0.77, 1.08)	98	⊕ ⊕ ⊕
	Epirubicin	Miriplatin	2	0.92 (0.86, 0.98)	247	⊕ ⊕ ⊕ ⊕
		Epirubicin + Cisplatin + Mitomycin + Furuorouracil	1	1.07 (0.88, 1.29)	51	⊕ ⊕ ⊕
		Epirubicin + Lobaplatin + Mitomycin	1	0.92 (0.84, 1.00)	244	⊕ ⊕ ⊕
		Ethanol	1	1.64 (1.23, 2.20)	97	⊕ ⊕ ⊕ ⊕
		Doxorubicin	1	1.07 (0.94, 1.22)	177	⊕ ⊕ ⊕ ⊕
	Doxorubicin	Bland	2	0.98 (0.92, 1.05)	184	⊕ ⊕ ⊕ ⊕
		Doxorubicin + Mitomycin	1	1.45 (0.57, 3.68)	109	⊕ ⊕ ⊕ ⊕
		Doxorubicin + Mitomycin + Gemcitabine	1	2.01 (0.66, 6.06)	103	⊕ ⊕ ⊕ ⊕
		Fluorouracil	1	0.85 (0.59, 1.22)	151	⊕ ⊕ ⊕
		Raltitrexed	1	1.15 (0.84, 1.57)	151	⊕ ⊕ ⊕
	Bland	Adriamycin	1	1.30 (0.95, 1.78)	249	⊕ ⊕ ⊕
		Cisplatin	2	0.76 (0.57, 1.02)	127	⊕ ⊕ ⊕
	Doxorubicin + Mitomycin	Doxorubicin + Mitomycin + Gemcitabine	1	1.31 (1.02, 1.69)	112	⊕ ⊕ ⊕ ⊕
	Raltitrexed	Fluorouracil	1	1.35 (0.97, 1.90)	152	⊕ ⊕ ⊕

**GRADE Working Group grades of evidence**
High quality (⊕ ⊕ ⊕ ⊕): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (⊕ ⊕ ⊕): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
**Low quality (⊕ ⊕): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**
**Very low quality (⊕): We are very uncertain about the estimate.**
*CI: confidence interval; HR: hazard ratio, MD: mean difference.

Supplementary Figures.

Supplementary Figure S1. Subgroup network connections of the included studies for the comparisons of the response rate according to mRECIST. (A) Connected comparisons of different interventions; (B) Connected comparisons of specific agents. "★" indicates the best anticancer agent.

Supplementary Figure S2. Subgroup network connections of included studies for comparisons of adverse events according to CTCAE Version 4.0 (A) Connections of different interventions; (B) Connections of specific agents. "★" indicates the best anticancer drug.

Supplementary Figure S3. Network connections of the included studies for comparisons of the overall survival rate. (A) Data for the 1-year (left panel) and 2-year (right panel) overall survival rates regarding different interventions; (B) Data for the 1-year (left panel) and 2-year (right panel) overall survival rates regarding specific agents. "★" indicates the most superior anticancer drug.

Supplementary Figure S4. Pair-wise meta-analysis for the single use of an anticancer agent compared with groups without anticancer drugs. (A) Data analysis of the response rate, (B) adverse events and (C) overall survival rate.

Supplementary Figure S5. Pair-wise meta-analysis for the combined use of anticancer drugs compared with single use. (A) Data analysis of the response rate, (B) adverse events and (C) overall survival rate.